Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, ...
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event on EmergingGrowth.com ...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (PMN), a biotechnology company focused on the generation and development of therapeutics ...
If you are interested in meeting with the Minerva team during the conference, please reach out to your Citizens Bank representative. A replay of the presentation will be available on the Company's ...
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for ...
Detailed price information for Promis Neurosciences Inc (PMN-Q) from The Globe and Mail including charting and trades.
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE)-- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™, a patented ...
Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, will ...
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results